Fred Hutch Cancer Center is leading the newly launched Vanguard Study, a national study of a new type of blood test that ...

Chemotherapy used to target and kill bladder cancer cells may trigger an inflammatory response that ultimately may make the cancer more resistant to treatment, according to new research from ...

Chemotherapy used to target and kill bladder cancer cells may trigger an inflammatory response that ultimately may make the ...

The New Brunswick, N.J., pharmaceutical giant on Thursday said the application covers TAR-200 for the treatment of patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle invasive ...

Discover a study exploring novel drug combinations and genetic insights transforming advanced bladder cancer treatment.

Discover a study that reveals a targetable CA125+ cell state in rare bladder cancer subtypes using single-cell RNA sequencing.

Bladder cancer is among the top 10 most common cancer types in the world, with approximately 573,000 new cases annually. Men ...

Johnson & Johnson (NYSE:JNJ) announced on Thursday that the U.S. FDA granted priority review for its new drug application aimed at getting marketing approval for TAR-200, a drug-releasing system for ...

Based on durable response data, TAR-200 has been given priority review for the treatment of patients with high-risk ...